l-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions

Biologicals

Volumn 38, Issue 1, 2010, Pages 150-157

  Bolli, Reinhard ^a   Woodtli, Karin ^a   Bärtschi, Michelle ^a   Höfferer, Liane ^a   Lerch, Peter ^a  

^a ZLB Behring AG   (Switzerland)

Author keywords

Antibody; Dimer; Intravenous immunoglobulin; l proline; Stability

Indexed keywords

DIMER; GLYCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PROLINE;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; LIQUID; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; ROOM TEMPERATURE; SCREENING;

ANTIBODIES; CHEMICAL PRECIPITATION; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; EXCIPIENTS; GLYCINE; HEPATITIS B SURFACE ANTIGENS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; PEPTIDE FRAGMENTS; PROLINE; PROTEIN MULTIMERIZATION; SOLUTIONS;

EID: 77649184666     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2009.09.002     Document Type: Article

References (43)

1. Gelfand E.W. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 6 (2006) 595-599
2. Jolles S., Sewell W.A.C., and Misbah S.A. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142 (2005) 1-11
3. Bonilla F.A., Bernstein I.L., Kahn D.A., Ballas Z.K., Chinen J., Frank M.M., et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94 (2005) S1-63
4. Schwartz S.A. Intravenous immunoglobulin treatment of immunodeficiency disorders. Pediatr Clin North Am 47 (2000) 1355-1369
5. Misra N., Bayry J., Ephrem A., Dasgupta S., Delignat S., Van Huyen J.P., et al. Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol 252 Suppl. 1 (2005) I1-I6
6. Burckhardt J.J., Gradi A., Oxelius A., Preud'homme J.L., Scherz R., Skvaril F., et al. Immunoglobulin G subclass distribution in three human immunoglobulin preparations. Vox Sang 57 (1989) 10-14
7. Hamilton R.G. Human IgG subclass measurements in the clinical laboratory. Clin Chem 33 (1987) 1707-1725
8. Hamrock D.J. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 6 (2006) 535-542
9. Spycher M.O., Bolli R., Hodler G., Gennari K., Hubsch A., and Späth P. Well-tolerated liquid intravenous immunoglobulin G preparations (IVIG) have a low immunoglobulin G dimer (IgG-dimer) content. J Autoimmun 96 Suppl. 1 (1996) 96
10. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 59 (2002) S28-S32
11. Gelfand E.W. Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs 28 (2005) 366-374
12. CSL Behring Ltd, Berne, Switzerland: Sandoglobulin 3g. Summary of Product Characteristics, 2008.
13. Daugherty A.L., and Mrsny R.J. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 58 (2006) 686-706
14. Tankersley D.L., Preston M.S., and Finlayson J.S. Immunoglobulin G dimer: an idio-type-anti-idiotype complex. Mol Immunol 25 (1988) 41-48
15. Tankersley D.L. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune disease. Immunol Rev 139 (1994) 159-172
16. Knezevic-Maramica I., and Kruskall M.S. Intravenous immune globulins: an update for clinicians. Transfusion 43 (2003) 1460-1480
17. Andresen I., Kovarik J.M., Spycher M., and Bolli R. Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations. J Clin Pharmacol 40 (2000) 722-730
18. Bleeker W.K., Teeling J.L., Verhoeven A.J., Rigter G.M.M., Agterberg J., Tool A.T.J., et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 95 (2000) 1856-1861
19. Kroez M., Kanzy E.J., Gronski P., and Dickneite G. Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals 31 (2003) 277-286
20. Bolli R., Spycher M.O., Brügger R., Wüst B., and Gennari K. IgG-dimer formation in liquid immunoglobulin preparations is inhibited by nicotinamide and other amphiphilic compounds. J Autoimmun 96 Suppl. 1 (1999) 96
21. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185 (1999) 129-188
22. Qi P., Volkan D.B., Zhao H., Nedved M.L., Hughes R., Bass R., et al. Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentrated liquid dosage form. J Pharm Sci 98 (2009) 3117-3130
23. Cohn E.J., Oncley J.L., Strong L.E., Hughes W.L., and Armstrong S.H. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J Clin Invest 23 (1944) 417-432
24. Kistler P., and Nitschmann H. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 7 (1962) 414-424
25. Stucki M., Boschetti N., Schäfer W., Hostettler T., Käsermann F., Nowak T., et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 36 (2008) 239-247
26. Stratford M.R.L., Dennis M.F., Hoskin J., Saunders M.I., Hodgkiss J.R., and Rojas A. Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. Acta Oncol 35 (1996) 213-219
27. Knip M., Douek I.F., Moore W.P.T., Gillmor H.A., McLean A.E.M., Bingley P.J., et al. Safety of high-dose nicotinamide: a review. Diabetologia 43 (2000) 1337-1345
28. Taneja S., and Ahmand F. Increased thermal stability of proteins in the presence of amino acids. Biochem J 303 (2003) 147-153
29. Arkawa T., and Timasheff S.N. The stabilization of protein by osmolytes. Biophys J 47 (1985) 411-414
30. Shiraki K., Kudou M., Fujiwara S., Imanaka T., and Takagi M. Biophysical effect of amino acids on the prevention of protein aggregation. J Biochem 132 (2002) 591-595
31. Kumar T.K., Samuel D., Jayaraman G., Srimathi T., and Yu C. The role of proline in the prevention of aggregation during protein folding in vitro. Biochem Mol Biol Int 46 (1998) 509-517
32. Boedeker B.G. Production processes of licensed recombinant factor VIII preparations. Semin Thromb Hemost 27 (2001) 385-394
33. Stucki M., Moudry R., Kempf C., Omar A., Schlegel A., and Lerch P.G. Characterisation of a chromatographically produced anti-D immunoglobulin product. J Chromatogr B Biomed Sci Appl 700 (1997) 241-248
34. Gronski P. IgG dimers in multi-donor derived immunoglobulins: aspects of generation and function. Curr Pharm Des 12 (2006) 181-190
35. Konova E., Atanasova M., Stoykov S., Velkova A., and Shoenfeld Y. Idiotypic and anti-idiotypic elastin autoantibodies: implications for IVIg and pregnancy loss. J Autoimmun 28 (2007) 46-54
36. Shoenfeld Y. Anti-DNA idiotypes: from induction of disease to novel therapeutical approaches. Immunol Lett 100 (2005) 73-77
37. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
38. Muramatsu K., Odagiri H., Morishita S., and Takeuchi H. Effect of excess levels of individual amino acids on growth of rats fed casein diets. J Nutr 101 (1971) 1117-1126
39. Spycher M.O., Kronthaler U., and Dickneite G. Investigation of potential neurological effects of stabilizers used in immunoglobulin products for intravenous use: comparison of L-proline and glycine. Ann Allergy Asthma Immunol 100 1 Suppl. 1 (2008) A83
40. Bolli R., Brügger R., Hodler G., Maeder W., Hubsch A., Spycher M.O., et al. IgG dimers in liquid intravenous immunoglobulin preparations. In: Kazatchkine M.D., and Morell A. (Eds). Intravenous immunoglobulin research and therapy (1996), The Parthenon Publishing Group, New York 307
41. ©) stabilized with L-proline. Vox Sang 96 (2009) 219-225
42. Stein M.R., Nelson R.P., Church J.A., Wasserman R.L., Borte M., Vermylen C., et al. IgPro10 in PID study group. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol 29 (2009) 137-144
43. Robak T., Salama A., Kovaleva L., Vyhovska Y., Davies S.V., Mazzucconi M.G., et al. International Privigen in ITP study group. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology 14 (2009) 227-236